SeamlessBio

Vesicle Transport Assay vs. ATPase Assay — Which Method for Which Question?

admin — Fri, 25 Sep 2026 10:10:10 +0000

Home/
Resources/
Vesicle Assay vs. ATPase Assay

DMPK Science · Assay Selection · Cell4Pharma

Both are established, both appear in regulatory submissions — and both produce false negatives that are easy to miss. A direct comparison.

Both assays use membrane preparations from cells overexpressing an ABC transporter. Both are established, both appear in regulatory submissions, and most transporter vendors offer both. That similarity causes a recurring problem in screening cascade design: the two methods measure different things and fail in different ways.

Choosing the wrong one produces false negatives that are easy to miss, because a negative result in either assay looks identical on paper.

What Each Assay Actually Measures

The vesicular transport assay measures transport. Inside-out vesicles accumulate a probe substrate in an ATP-dependent manner. You quantify how much substrate ends up inside the vesicle. A test compound that reduces that accumulation is an inhibitor; a compound that accumulates itself is a substrate.

The ATPase assay measures ATP consumption. ABC transporters hydrolyse ATP as they cycle. The assay quantifies released inorganic phosphate, typically colorimetrically. A compound that stimulates ATPase activity is interacting with the transporter; a compound that suppresses baseline activity is interfering with the cycle.

The distinction matters: the vesicular assay observes the outcome, the ATPase assay observes the engine. Engine activity does not always translate into movement.

Side by Side

	Vesicular transport	ATPase
Readout	Substrate accumulation inside vesicles	Inorganic phosphate release
Nature	Direct	Indirect
Substrate vs. inhibitor	Distinguishes clearly	Only partially
Throughput	Moderate to high (inhibition mode)	High
Detection	Radiolabel, fluorescence or LC-MS/MS	Plate reader (colorimetric)
Radiochemistry needed	Often	No
Main failure mode	High-permeability compounds escape the vesicle	Slowly transported compounds give no signal
Use for regulatory IC₅₀	Established	Supporting evidence

Where the ATPase Assay Fails

The ATPase assay is fast, inexpensive and needs no radiochemistry infrastructure. Its weakness is specific and well documented.

Slowly transported substrates go undetected

Some compounds are transported so slowly that they generate no measurable increase in ATP hydrolysis above baseline, yet they are genuine substrates. Cyclosporin A is the standard example — unremarkable in the ATPase assay, clearly interacting in the vesicular assay.

High baseline activity masks weak effects

Certain transporters, P-gp in particular, show substantial constitutive ATPase activity. A modest stimulation can disappear into that noise.

The stimulation curve is not always interpretable

Responses come in several shapes — classical Michaelis-Menten, bell-shaped with high-concentration inhibition, flat, or suppressive. A bell-shaped curve can read as either substrate or inhibitor depending on the concentration range tested.

Where the Vesicular Assay Fails

The mirror-image weakness is passive permeability.

Vesicles are small and their membranes are lipid bilayers. A highly lipophilic, highly permeable compound transported into the vesicle diffuses straight back out before it can be measured. The compound is a genuine substrate; the assay reports nothing.

This is why substrate assays in the vesicular format are only reliable for compounds of low to moderate passive permeability. For a permeable compound you need a cell-based system — Caco-2, MDCK-MDR1 or a transfected line — where the transporter works across an intact polarised monolayer and efflux ratio is the readout.

Inhibition assays are far less affected. There the probe substrate is chosen for suitable permeability, and the test compound only has to reach the binding site. This is why vesicular inhibition assays are robust and widely used for IC₅₀ determination, while vesicular substrate assays carry caveats.

Choosing

Situation	Method
Early triage of large compound numbers, no radiochemistry facility	ATPase — but treat negatives with caution
IC₅₀ for regulatory submission (BSEP, BCRP, P-gp, MRP family)	Vesicular transport
Substrate status of a high-permeability compound	Cell-based (Caco-2, MDCK-MDR1)
Modelling a polarised barrier — intestine, canaliculus, BBB	Cell-based
Renal transporter DDI (OAT1, OAT3, OCT2, MATE)	Cell-based — ciPTEC

Most well-designed cascades use two of the three. A common pattern: ATPase for early triage, vesicular for IC₅₀ confirmation on advanced compounds, cell-based for substrate determination where permeability rules out the vesicular format.

What Regulators Expect

ICH M12 (2023) harmonises FDA and EMA requirements for transporter-mediated drug interactions. For efflux transporters, P-gp and BCRP assessment is expected for new molecular entities.

The guidance does not mandate one assay format. In practice, IC₅₀ values submitted for efflux transporter DDI assessment come predominantly from vesicular transport or cell-based efflux systems. ATPase data typically appears as supporting mechanistic evidence rather than as the primary determination.

If your data package will drive a DDI decision, generate it in the vesicular or cell-based format. Our overview of DMPK and ABC transporter assays maps which transporters are required for which submission type.

Practical Notes for the Vesicular Assay

Always run control vesicles. ATP-dependent transport is the difference between transporter vesicles and non-transfected controls. Without the subtraction the number is not usable — see the Human Control Vesicle Kit.
AMP is the correct negative condition, not ATP omission — it keeps the ionic environment comparable.
Watch lot-to-lot transport ratios. The ATP/AMP ratio is the practical quality metric; a low ratio compresses the assay window and inflates IC₅₀ variability.
The expression system matters. Glycosylation and membrane lipid composition differ between host cells — see HEK293 vs. Sf9 vesicles.
Match detection to the question. Radiolabel remains the reference for regulatory work, fluorescence suits screening, LC-MS/MS handles compounds that cannot be labelled.

Frequently Asked Questions

Can I use ATPase data in a regulatory submission?

As supporting mechanistic evidence, yes. As the primary IC₅₀ determination for a DDI decision, it is not the expected format — reviewers look for vesicular or cell-based data.

Why did my compound show nothing in the ATPase assay but a clear effect in the vesicular assay?

Most likely a slowly transported substrate. It moves through the transporter without generating ATP hydrolysis above baseline. Cyclosporin A behaves this way. A negative ATPase result does not rule out interaction.

My compound is highly lipophilic. Can I still use the vesicular assay?

For inhibition studies, yes — the test compound only needs to reach the binding site. For substrate determination, no: it will diffuse back out of the vesicle before measurement. Use a cell-based efflux system instead.

Which transporters can be assessed in the vesicular format?

The efflux transporters: P-gp (ABCB1), BCRP (ABCG2), BSEP (ABCB11) and the MRP family (MRP1–MRP8). Uptake transporters such as OATP, OAT and OCT require cell-based systems.

Do I need radiochemistry infrastructure?

Not necessarily. Radiolabel remains the reference method, but fluorescent probe substrates are available for several transporters and work on a standard plate reader. LC-MS/MS is the third option for unlabelled compounds.

HEK293 vs. Sf9 Vesicles →
BSEP Inhibition & DILI →
ABC Transporter Vesicle Kits →
Human Control Vesicle Kit →
ciPTEC Cell-Based Assays →
SOLVO Alternative Compared →
DMPK & ABC Transporter Assays →
Assay Service →

Vesicle kits from EU stock

BSEP, BCRP, P-gp, MRP1–MRP8 and control vesicles — HEK293-derived, 100 reactions per kit, lot-specific activity data.

Request a quote

Der Beitrag Vesicle Transport Assay vs. ATPase Assay — Which Method for Which Question? erschien zuerst auf SeamlessBio.

Vesicular transport assay vs cell-based assay

admin — Fri, 25 Sep 2026 09:40:30 +0000

August 2026 · 9 min read

You need to assess whether your drug candidate interacts with an ABC efflux transporter. Three in vitro methods are available: the vesicular transport assay, the cell-based monolayer assay, and the ATPase assay. Each works — but each has a specific permeability window, throughput profile, and regulatory acceptance level that makes it the right choice for some compounds and the wrong choice for others.

This guide explains exactly when to use which — with a decision framework you can apply directly to your compound series.

The three methods — a brief overview

All three assay formats are designed to detect interactions between a drug candidate and an ABC transporter. They differ in how they measure that interaction.

Vesicular transport assay (membrane vesicle assay)

Inside-out membrane vesicles are prepared from insect cells (typically Sf9) or mammalian cells (HEK293) that overexpress a specific ABC transporter. During the preparation process, the membrane is inverted — placing the substrate-binding site of the transporter on the outside of the vesicle. When ATP is added, the transporter actively pumps its substrate into the interior of the vesicle. The amount of substrate accumulated inside the vesicle — measured after rapid filtration — is the direct readout of transporter activity.

Inhibition is measured by adding a test compound alongside the probe substrate and quantifying the reduction in vesicular accumulation. In a vesicular transport setting, passive permeability of the compound does not affect apparent inhibitory potential — a critical advantage over cell-based assays for lipophilic compounds.

Cell-based monolayer assay (bidirectional transport)

Polarised cell monolayers — typically Caco-2, MDCKII-MDR1, or LLC-MDR1 — are grown on permeable filter inserts. The compound is applied to either the apical (A) or basolateral (B) compartment, and transport in both directions is measured after a defined incubation period. An efflux ratio (B→A / A→B) greater than 2 indicates active transporter involvement. The ratio is reduced in the presence of a selective inhibitor to confirm transporter specificity.

ATPase assay

ABC transporters hydrolyse ATP to power substrate translocation. The ATPase assay measures this hydrolysis indirectly by quantifying the inorganic phosphate (Pi) released. Transported substrates increase baseline ATPase activity, while inhibitors or slowly transported compounds inhibit baseline ATPase activity and/or the ATPase activity measured in the presence of a stimulating agent — allowing the assay to determine whether a compound acts as a substrate and/or inhibitor.

The permeability problem — why it determines your method

The most important variable in ABC transporter assay method selection is the passive permeability of your compound. This is not optional guidance — it directly determines whether your assay will generate meaningful data or artefactual results.

High permeability compounds (logP >3, Papp >20 × 10⁻⁶ cm/s): In a cell-based assay, these compounds cross the monolayer so rapidly by passive diffusion that efflux transporter activity is masked — the efflux ratio is compressed toward 1.0 regardless of transporter interaction. The vesicular transport assay avoids this problem entirely because passive permeability of the compound does not affect apparent inhibitory potential in a vesicular transport setting.
Low permeability compounds (logP <1, Papp <2 × 10⁻⁶ cm/s): In the vesicular transport assay, these compounds may accumulate inside vesicles through non-specific trapping rather than active transport — creating false positive substrate results. The cell-based assay is more appropriate here because the intact cell provides a physiologically relevant barrier.
Medium permeability compounds: Both assays perform reliably. Method choice is driven by throughput, regulatory context, and the specific transporter being studied.

Full comparison — vesicular transport vs. cell-based vs. ATPase

Parameter	Vesicular Transport	Cell-Based Monolayer	ATPase
Principle	Active accumulation into inside-out vesicles (ATP-dependent)	Bidirectional transport across cell monolayer (efflux ratio)	Measurement of ATP hydrolysis (Pi release)
Best compound permeability	Low to medium	Medium; problematic for very high or very low Papp	Any — permeability-independent
Detects substrate?	Yes (direct format with radiolabel or LC-MS)	Yes (efflux ratio >2)	Yes (ATPase activation)
Detects inhibitor?	Yes (IC50 in inhibitory format)	Yes (efflux ratio reduction)	Yes (ATPase inhibition)
Throughput	Medium-high (96-well, same-day IC50)	Low-medium (4–21 day cell growth required)	High (colorimetric, simple readout)
Turnaround	Same day — membranes stored at −80°C indefinitely and thawed on demand	Days to weeks (cell culture preparation)	Same day
FDA/EMA regulatory acceptance	Accepted for BSEP, MRP2–4, P-gp, BCRP	Preferred for P-gp and BCRP substrate identification	Accepted as supporting data; not standalone for DDI submission
Effect of P-gp expression level	IC50 independent of transporter expression level	IC50 depends on transporter expression — source-dependent variability	Depends on membrane preparation quality
Suitable for	BSEP, MRP2, MRP3, MRP4, MRP5, MRP8, BCRP, P-gp	P-gp (MDR1), BCRP — substrate studies	P-gp (ABCB1), BCRP — early screening
Limitation	False positives for highly permeable compounds in substrate assay	Not suitable for high Papp compounds; long setup time	Nonlinear relationship between ATPase activity and transport rate; not standalone for regulatory submission
Cost	Low-medium per sample	Medium-high (cell culture infrastructure)	Low (colorimetric, simple equipment)

Which transporters require which method?

Not all transporters can be studied with all three methods. The transporter’s biology and its expression system determine which assay format is technically feasible.

Transporter	Gene	Recommended method	Why
BSEP	ABCB11	Vesicular transport	Hepatocyte-specific; no reliable cell monolayer model. Vesicle assay is FDA/EMA standard for BSEP/DILI assessment
MRP2	ABCC2	Vesicular transport	Inside-out vesicles provide clean assay window; vacuum filtration system offers rapid and reliable means for screening drug candidates for DILI risk
MRP3, MRP4	ABCC3, ABCC4	Vesicular transport	No standard cell monolayer model; vesicle assay is the practical option
P-gp (MDR1)	ABCB1	Cell-based (substrate) or vesicular (inhibitor/high Papp)	FDA prefers cell-based for substrate ID; vesicular transport preferred for high permeability compounds where efflux ratio is compressed
BCRP	ABCG2	Cell-based (substrate) or vesicular (inhibitor)	Several BCRP substrates and inhibitors are of low passive permeability, and the vesicular transport assay works well in this permeability space
MRP1, MRP5, MRP8	ABCC1, ABCC5, ABCC8	Vesicular transport	No standard cell model; vesicle kits from Cell4Pharma available

The decision framework — step by step

Apply these four questions in sequence to select the right assay for your compound:

Which transporter are you studying?
If BSEP, MRP2, MRP3, MRP4, MRP5, MRP8 → vesicular transport assay only (no cell model available).
If P-gp or BCRP → continue to question 2.
What is the passive permeability of your compound?
Papp <5 × 10⁻⁶ cm/s (low) → vesicular transport or cell-based both valid; vesicular preferred for throughput.
Papp >20 × 10⁻⁶ cm/s (high) → vesicular transport only; cell-based will give false-negative efflux ratio.
Medium Papp → both valid; continue to question 3.
Substrate or inhibitor study?
Substrate identification → cell-based monolayer preferred (FDA guidance for P-gp/BCRP).
Inhibitor IC50 → vesicular transport assay preferred (expression-independent IC50, same-day turnaround).
What is your regulatory context?
IND-enabling DMPK package → use FDA/EMA-accepted methods per transporter (see table above).
Early discovery screening → ATPase assay acceptable as high-throughput rank-ordering tool.
DILI risk assessment (BSEP/MRP2) → vesicular transport assay required.

The ATPase assay: useful — but not standalone

The ATPase assay is valuable for early-phase high-throughput screening when you need to rank-order a large compound series for transporter interaction quickly and cheaply. It requires no specialised equipment beyond a plate reader and generates same-day results.

Its limitations are important to understand: ATPase assays are challenged by the nonlinear relationship of ATPase activity and transport rate. This means that ATPase activation does not linearly predict transport rate, and ATPase inhibition at high compound concentrations can occur through mechanisms unrelated to transporter inhibition (e.g. non-specific membrane effects). For regulatory DDI submissions, the ATPase assay is accepted as supporting data but is not sufficient as a standalone method for P-gp or BCRP interaction characterisation.

The correct workflow: use the ATPase assay to filter your compound series early, then confirm hits with vesicular transport or cell-based assay as appropriate for regulatory submission.

Ready-to-use vesicle kits for in-house DMPK

Running vesicular transport assays in-house has historically required significant infrastructure for membrane preparation. Ready-to-use vesicle kits eliminate this barrier — pre-prepared, quality-controlled inside-out membrane vesicles that simply need to be thawed before use.

SeamlessBio distributes the Cell4Pharma ABC Transporter Vesicle Kit series for in-house DMPK testing across the full panel of clinically relevant efflux transporters:

BSEP Vesicle Kit — bile salt export pump; DILI risk assessment per FDA/EMA guidance
P-gp Vesicle Kit — MDR1/ABCB1; high Papp compound inhibition studies
BCRP Vesicle Kit — ABCG2; low permeability substrate/inhibitor studies
MRP1 Vesicle Kit — ABCC1
MRP2 Vesicle Kit — ABCC2; hepatic efflux, cholestasis risk
MRP3 Vesicle Kit — ABCC3
MRP4 Vesicle Kit — ABCC4
MRP5 Vesicle Kit — ABCC5
MRP8 Vesicle Kit — ABCC8
Control Vesicle Kit — non-transfected membrane control for background subtraction

Each kit contains 100 reactions, validated probe substrates, ATP regenerating system, and assay buffer. Membranes stored at −80°C; stable for 12 months. Full assay protocol and QC data included.

→ View the full Cell4Pharma kit portfolio at SeamlessBio

Summary — the three-line decision rule

BSEP, MRP2–5, MRP8: vesicular transport assay — no cell model available, this is your only option
P-gp or BCRP substrate: cell-based monolayer — FDA/EMA preferred for substrate identification
P-gp or BCRP inhibitor, high Papp compound, or IND-enabling IC50: vesicular transport assay — expression-independent, same-day, regulatory-accepted

Further reading on seamlessbio.de:

Questions about kit selection for your compound or assay setup? Contact us at info@seamlessbio.de or request a quote.

Der Beitrag Vesicular transport assay vs cell-based assay erschien zuerst auf SeamlessBio.

What is Animal Component-Free (ACF) Cell Culture?

admin — Thu, 24 Sep 2026 23:00:00 +0000

Animal component-free (ACF) cell culture refers to the practice of culturing cells using media and supplements that contain no materials derived from animals — including no FBS, no animal-derived serum albumin, and no animal-origin growth factors. ACF culture systems are increasingly required in cell therapy manufacturing, where xenogeneic materials introduce safety and regulatory risks.

Why ACF Matters in Modern Bioprocessing

FBS contains undefined growth factors, hormones, and proteins that introduce variability and potential contamination risks (mycoplasma, viruses, prions). For therapeutic cell products intended for human administration, animal-derived components are scrutinized by regulators and must be minimized or eliminated. ACF systems offer better batch consistency, improved traceability, and reduced regulatory burden.

ACF Alternatives to FBS

Key ACF alternatives include human platelet lysate (HPL) for MSC and T cell expansion, recombinant human albumin (rHSA) in place of BSA, defined synthetic media supplemented with recombinant growth factors, and chemically defined media for specific cell lines such as CHO and HEK293.

ACF vs. Xeno-Free

“Xeno-free” means no materials from a foreign species are used (so human-derived HPL qualifies), while “ACF” means no animal-derived materials at all. For allogeneic cell therapy, xeno-free is typically the minimum requirement; ACF is the more stringent standard.

→ Explore Cell Culture Solutions

Der Beitrag What is Animal Component-Free (ACF) Cell Culture? erschien zuerst auf SeamlessBio.

What is Xeno-Free Cell Culture?

admin — Thu, 24 Sep 2026 23:00:00 +0000

Xeno-free (XF) cell culture refers to the use of culture media and supplements that contain no materials derived from a species other than the target cell donor species. For human cell culture — including stem cell expansion and T cell manufacturing — xeno-free means no bovine-, porcine-, or other non-human-animal-derived components. Human-derived materials such as human platelet lysate (HPL) are considered xeno-free.

Xeno-Free vs. Animal Component-Free (ACF)

Xeno-free is a less stringent requirement than ACF. A xeno-free medium may still contain human-derived serum or growth factors, whereas ACF excludes all animal-origin materials, including human-derived ones. In practice, most regulatory guidance for cell therapy focuses on xeno-free as the minimum requirement for products intended for human use.

Regulatory Drivers

EMA and FDA guidance for ATMP manufacturing increasingly discourages xenogeneic components due to the risk of xenogeneic immunogenicity and unknown viral contamination from non-human sources. Xeno-free systems reduce regulatory burden and simplify the risk assessment for marketing authorization applications.

Practical Implementation

Transitioning from FBS to xeno-free conditions typically involves replacing FBS with HPL or a defined recombinant supplement, re-optimizing seeding density and passage number, and validating the xeno-free process for equivalence in cell identity and function.

→ Explore Cell Culture Solutions

Der Beitrag What is Xeno-Free Cell Culture? erschien zuerst auf SeamlessBio.

What is rHSA (Recombinant Human Serum Albumin)?

admin — Thu, 24 Sep 2026 23:00:00 +0000

Recombinant human serum albumin (rHSA) is a biotechnology-derived form of human serum albumin produced by expression in yeast (Saccharomyces cerevisiae or Pichia pastoris) or mammalian cells (CHO). It is chemically and functionally equivalent to plasma-derived HSA but is produced without human plasma, eliminating the risk of blood-borne pathogen transmission.

Advantages Over Plasma-Derived HSA

rHSA offers consistent purity (≥98%), defined fatty acid profile, no risk of viral contamination from plasma donors, and full traceability of the production process. It is the preferred albumin source for GMP cell culture, IVD diagnostics, and drug formulation applications where plasma-derived materials are undesirable.

rHSA Grades

Research Grade rHSA is suitable for cell culture supplementation, media formulation, and assay development. GMP-Grade rHSA is produced under GMP conditions with full documentation for use in clinical manufacturing. Economy Grade rHSA offers a cost-effective option for high-volume research applications.

Applications

rHSA is used as a carrier protein in cell culture media, a stabilizer in vaccine formulations, a component of diagnostic calibrators and controls, and a carrier for drug delivery formulations.

→ View Recombinant HSA Products

Der Beitrag What is rHSA (Recombinant Human Serum Albumin)? erschien zuerst auf SeamlessBio.

What is Recombinant Human Transferrin?

admin — Thu, 24 Sep 2026 23:00:00 +0000

Recombinant human transferrin is a biotechnology-derived iron-transport glycoprotein functionally equivalent to plasma-derived human transferrin (hTF). It is produced by expression in rice, yeast, or CHO cells and is used as a key supplement in serum-free and chemically defined cell culture media to deliver iron to cells without the use of animal-derived serum.

Role of Transferrin in Cell Culture

Transferrin binds ferric iron (Fe³⁺) in the extracellular environment and delivers it to cells via receptor-mediated endocytosis. Iron is essential for cellular respiration, DNA synthesis, and proliferation. Without transferrin, cells cannot efficiently acquire iron from the culture medium, leading to reduced growth and productivity.

Recombinant vs. Plasma-Derived Transferrin

Plasma-derived transferrin carries the risk of lot-to-lot variability and potential contamination from human plasma. Recombinant transferrin eliminates these risks and offers consistent iron saturation levels and molecular uniformity, making it the preferred choice for GMP cell culture and regulatory-compliant media formulations.

Applications

Recombinant transferrin is a standard component of serum-free media for CHO, HEK293, hybridoma, and stem cell cultivation, as well as GMP media for ATMP manufacturing.

→ Explore Albumin & Protein Products

Der Beitrag What is Recombinant Human Transferrin? erschien zuerst auf SeamlessBio.

What is Disease State Serum?

admin — Thu, 24 Sep 2026 23:00:00 +0000

Disease state serum is human serum collected from donors with a confirmed medical condition — such as autoimmune diseases, infectious diseases, cancer, or metabolic disorders — and used in in vitro diagnostic (IVD) assay development, calibration, and quality control. It provides a biologically relevant matrix that reflects the complexity of patient samples better than defined synthetic controls.

Applications of Disease State Serum

Disease state serum is used as a positive control material in immunoassays (ELISA, chemiluminescence, lateral flow), as a matrix for spiking experiments to assess assay specificity and cross-reactivity, and as a reference material in assay validation studies per CLSI and IVDR guidelines.

Common Disease State Categories

Typical categories include autoimmune disease sera (ANA-positive, rheumatoid factor-positive), infectious disease sera (HIV, HBV, HCV antibody-positive for research use), lipemic and icteric sera for interference testing, and oncology-related sera for tumor marker assay development.

Regulatory Context

Under the EU IVDR (In Vitro Diagnostic Regulation 2017/746), IVD manufacturers must demonstrate performance using clinically relevant samples. Disease state sera with confirmed donor status are essential reference materials for this purpose.

→ View Human Serum Products

Der Beitrag What is Disease State Serum? erschien zuerst auf SeamlessBio.

What is Normal Goat Serum (NGS)?

admin — Thu, 24 Sep 2026 23:00:00 +0000

Normal goat serum (NGS) is serum collected from healthy, non-immunized goats and used in immunohistochemistry (IHC), immunofluorescence (IF), flow cytometry, and ELISA as a blocking agent. It reduces non-specific background staining by saturating non-specific binding sites on tissue sections or assay surfaces before the application of the primary antibody.

Why Use Normal Serum for Blocking?

Non-specific staining in antibody-based assays occurs when the secondary antibody — or the primary antibody itself — binds to Fc receptors, charged molecules, or other non-target proteins in the sample. Applying a blocking serum derived from the same species as the secondary antibody saturates these sites, reducing background without interfering with the target epitope.

When to Choose Normal Goat Serum

NGS is the appropriate blocking choice when the secondary antibody is raised in goat (e.g., goat anti-rabbit IgG, goat anti-mouse IgG). It is one of the most widely used blocking sera in molecular biology due to the broad availability of goat-derived secondary antibodies.

Usage Protocol

Typically, a 2–5% solution of NGS in PBS is applied to the sample for 30–60 minutes at room temperature before primary antibody incubation. NGS should not be used when the primary antibody itself is raised in goat.

→ View Goat Serum Products

Der Beitrag What is Normal Goat Serum (NGS)? erschien zuerst auf SeamlessBio.

What is Gamma-Irradiated FBS?

admin — Thu, 24 Sep 2026 23:00:00 +0000

Gamma-irradiated FBS (fetal bovine serum) has been treated with ionizing gamma radiation — typically at a dose of 25–45 kGy — to inactivate potential viral contaminants, mycoplasma, and other adventitious agents. It is used in GMP manufacturing, viral vector production, and vaccine manufacturing where an additional viral safety step is required beyond standard sterile filtration.

How Does Gamma Irradiation Work?

Gamma rays generate free radicals that damage nucleic acids (DNA and RNA) in microorganisms, rendering them unable to replicate. At the doses used for FBS irradiation, the serum proteins — albumin, immunoglobulins, growth factors — retain most of their biological activity, although some reduction in heat-labile growth factor activity may occur.

When Is Gamma-Irradiated FBS Required?

Gamma-irradiated FBS is specified when: manufacturing cell-based vaccines or viral vectors where adventitious viral contamination must be minimized; GMP processes requiring a validated viral inactivation step in raw materials; or regulatory submissions requiring documented viral safety for serum-containing media.

Performance Considerations

Gamma irradiation may slightly reduce the concentration of certain growth factors. Lot-specific performance testing on your cell line is recommended, and SeamlessBio can provide test samples before lot reservation.

→ View Gamma-Irradiated FBS

Der Beitrag What is Gamma-Irradiated FBS? erschien zuerst auf SeamlessBio.

What is Low Endotoxin FBS?

admin — Thu, 24 Sep 2026 23:00:00 +0000

Low endotoxin FBS is fetal bovine serum that has been tested and qualified to contain endotoxin levels below a defined threshold — typically <5 EU/mL, compared to standard FBS which may contain up to 25–100 EU/mL. Endotoxins (lipopolysaccharides, LPS) are bacterial cell wall components that trigger innate immune responses and can significantly alter cell behavior in culture.

Why Endotoxin Matters in Cell Culture

Even sub-nanogram concentrations of endotoxin can activate TLR4 signaling in macrophages, dendritic cells, and endothelial cells, causing cytokine release, altered gene expression, and compromised experimental reproducibility. For immunology research, PBMC culture, and cytokine studies, endotoxin contamination produces artifactual results.

When to Use Low Endotoxin FBS

Low endotoxin FBS is recommended for: primary immune cell culture (PBMC, macrophages, dendritic cells), cytokine release assays, NF-κB signaling studies, ATMP manufacturing, and any application where innate immune activation would interfere with the experiment.

Ultra-Low Endotoxin FBS

Ultra-low endotoxin FBS is typically specified at <1 EU/mL and is required for the most sensitive immunological assays and GMP manufacturing where endotoxin specifications are stringent.

→ View Low Endotoxin FBS

Der Beitrag What is Low Endotoxin FBS? erschien zuerst auf SeamlessBio.

SeamlessBio

Vesicle Transport Assay vs. ATPase Assay — Which Method for Which Question?

What Each Assay Actually Measures

Side by Side

Where the ATPase Assay Fails

Slowly transported substrates go undetected

High baseline activity masks weak effects

The stimulation curve is not always interpretable

Where the Vesicular Assay Fails

Choosing

What Regulators Expect

Practical Notes for the Vesicular Assay

Frequently Asked Questions

Related

Vesicle kits from EU stock

Vesicular transport assay vs cell-based assay

The three methods — a brief overview

Vesicular transport assay (membrane vesicle assay)

Cell-based monolayer assay (bidirectional transport)

ATPase assay

The permeability problem — why it determines your method

Full comparison — vesicular transport vs. cell-based vs. ATPase

Which transporters require which method?

The decision framework — step by step

The ATPase assay: useful — but not standalone

Ready-to-use vesicle kits for in-house DMPK

Summary — the three-line decision rule

What is Animal Component-Free (ACF) Cell Culture?

Why ACF Matters in Modern Bioprocessing

ACF Alternatives to FBS

ACF vs. Xeno-Free

What is Xeno-Free Cell Culture?

Xeno-Free vs. Animal Component-Free (ACF)

Regulatory Drivers

Practical Implementation

What is rHSA (Recombinant Human Serum Albumin)?

Advantages Over Plasma-Derived HSA

rHSA Grades

Applications

What is Recombinant Human Transferrin?

Role of Transferrin in Cell Culture

Recombinant vs. Plasma-Derived Transferrin

Applications

What is Disease State Serum?

Applications of Disease State Serum

Common Disease State Categories

Regulatory Context

What is Normal Goat Serum (NGS)?

Why Use Normal Serum for Blocking?

When to Choose Normal Goat Serum

Usage Protocol

What is Gamma-Irradiated FBS?

How Does Gamma Irradiation Work?

When Is Gamma-Irradiated FBS Required?

Performance Considerations

What is Low Endotoxin FBS?

Why Endotoxin Matters in Cell Culture

When to Use Low Endotoxin FBS

Ultra-Low Endotoxin FBS